Literature DB >> 16695324

STUDIES OF STREPTOCOCCAL FIBRINOLYSIS. II. THE INHIBITION OF STREPTOCOCCAL FIBRINOLYSIS BY ANTIFIBRINOLYSIN AND ANTIPROTEASE.

M H Kaplan1.   

Abstract

Year:  1946        PMID： 16695324      PMCID： PMC435570          DOI： 10.1172/JCI101714

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


× No keyword cloud information.
  10 in total

1.  THE FIBRINOLYTIC ACTIVITY OF HEMOLYTIC STREPTOCOCCI.

Authors:  W S Tillett
Journal:  Bacteriol Rev       Date:  1938-12

2.  Studies on Streptococcal Fibrinolysis.

Authors:  J D Le Mar; M F Gunderson
Journal:  J Bacteriol       Date:  1940-06       Impact factor: 3.490

3.  FIBRINOLYTIC ACTIVITY OF HEMOLYTIC STREPTOCOCCI. THE DEVELOPMENT OF RESISTANCE TO FIBRINOLYSIS FOLLOWING ACUTE HEMOLYTIC STREPTOCOCCUS INFECTIONS.

Authors:  W S Tillett; L B Edwards; R L Garner
Journal:  J Clin Invest       Date:  1934-01       Impact factor: 14.808

4.  CHEMICAL, CLINICAL, AND IMMUNOLOGICAL STUDIES ON THE PRODUCTS OF HUMAN PLASMA FRACTIONATION. I. THE CHARACTERIZATION OF THE PROTEIN FRACTIONS OF HUMAN PLASMA.

Authors:  E J Cohn; J L Oncley; L E Strong; W L Hughes; S H Armstrong
Journal:  J Clin Invest       Date:  1944-07       Impact factor: 14.808

5.  STUDIES ON BLOOD COAGULATION: A PROTEOLYTIC ENZYME PREPARED FROM CALCIUM AND PLATELET FREE NORMAL HUMAN BLOOD PLASMA.

Authors:  H J Tagnon; C S Davidson; F H Taylor
Journal:  J Clin Invest       Date:  1942-09       Impact factor: 14.808

6.  THE RESISTANCE TO FIBRINOLYTIC ACTIVITY OF THE HEMOLYTIC STREPTOCOCCUS WITH SPECIAL REFERENCE TO PATIENTS WITH RHEUMATIC FEVER AND RHEUMATOID (ATROPHIC) ARTHRITIS.

Authors:  W K Myers; C S Keefer; W F Holmes
Journal:  J Clin Invest       Date:  1935-01       Impact factor: 14.808

7.  THE STREPTOCOCCAL ANTIFIBRINOLYSIN TEST IN CLINICAL USE.

Authors:  P L Boisvert
Journal:  J Clin Invest       Date:  1940-01       Impact factor: 14.808

8.  STUDIES OF STREPTOCOCCAL FIBRINOLYSIS. I. THE DISSIMILARITY OF SERUM PROTEASE AND TRYPSIN AS INDICATED BY THE SEPARATE SPECIFICITIES OF THEIR KINASES, FIBRINOLYSIN AND ENTEROKINASE.

Authors:  M H Kaplan
Journal:  J Clin Invest       Date:  1946-05       Impact factor: 14.808

9.  DEVELOPMENT OF ANTIFIBRINOLYTIC PROPERTIES IN BLOOD OF PATIENTS WITH RHEUMATIC FEVER, CHRONIC INFECTIVE ARTHRITIS AND BACTERIAL ENDOCARDITIS.

Authors:  E Waaler
Journal:  J Clin Invest       Date:  1937-01       Impact factor: 14.808

10.  INHIBITION OF beta HEMOLYTIC STREPTOCOCCI FIBRINOLYSIN BY TRYPSIN INHIBITOR (ANTIPROTEASE).

Authors:  I A Mirsky
Journal:  Science       Date:  1944-09-01       Impact factor: 47.728
  10 in total
  6 in total

1.  A STUDY OF ANTIFIBRINOLYSIN ACTIVITY IN THE PLASMAS OF VARIOUS ANIMAL SPECIES.

Authors:  M M Guest; B M Daly; A G Ware; W H Seegers
Journal:  J Clin Invest       Date:  1948-11       Impact factor: 14.808

2.  STUDIES OF STREPTOCOCCAL FIBRINOLYSIS. I. THE DISSIMILARITY OF SERUM PROTEASE AND TRYPSIN AS INDICATED BY THE SEPARATE SPECIFICITIES OF THEIR KINASES, FIBRINOLYSIN AND ENTEROKINASE.

Authors:  M H Kaplan
Journal:  J Clin Invest       Date:  1946-05       Impact factor: 14.808

3.  STUDIES OF STREPTOCOCCAL FIBRINOLYSIS. IV. CLINICAL APPLICATION OF A QUANTITATIVE ANTIFIBRINOLYSIN TEST.

Authors: 
Journal:  J Clin Invest       Date:  1946-05       Impact factor: 14.808

4.  QUANTITATIVE ANTISTREPTOKINASE STUDIES IN PATIENTS INFECTED WITH GROUP A HEMOLYTIC STREPTOCOCCI: A COMPARISON WITH SERUM ANTISTREPTOLYSIN AND GAMMA GLOBULIN LEVELS WITH SPECIAL REFERENCE TO THE OCCURRENCE OF RHEUMATIC FEVER.

Authors:  H C Anderson; H G Kunkel; M McCarty
Journal:  J Clin Invest       Date:  1948-07       Impact factor: 14.808

5.  STUDIES OF STREPTOCOCCAL FIBRINOLYSIS. III. A QUANTITATIVE METHOD FOR THE ESTIMATION OF SERUM ANTIFIBRINOLYSIN.

Authors:  M H Kaplan
Journal:  J Clin Invest       Date:  1946-05       Impact factor: 14.808

6.  Studies on a proteolytic enzyme system of the blood. I. Inhibition of fibrinolysin.

Authors:  J H LEWIS; J H FERGUSON
Journal:  J Clin Invest       Date:  1950-04       Impact factor: 14.808
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.